Grant awarded to research centre to create lab-on-a-chip technology
Posted: 24 May 2022 | Ria Kakkad (Drug Target Review) | No comments yet
A research centre based at the University of Kansas has been awarded $6.6 million to create lab-on-a-chip technology for medical tests.


A research centre based at the University of Kansas, US, that develops rapid next-generation tests for a host of human ailments recently earned $6.6 million in continued funding over the next five years from the US National Institutes of Health’s National Institute of Biomedical Imaging and Bioengineering (NIBIB) as a US National Biotechnology Resource (P41) Center. The grant has been awarded to the centre to create lab-on-a-chip technology.
The Center of BioModular Multi-Scale Systems for Precision Medicine, (CBM), takes small plastic chips made of the same material as a compact disc and transforms them into marvels of engineering and chemistry that quickly can detect hard-to-diagnose human diseases using saliva, urine, or blood from a patient. The liquid biopsies can detect circulating tumour cells, cell-free DNA, viruses, and vesicles that are released by biological cells associated with a particular disease.
“We develop little $2 widgets made from a plastic by injection moulding that can take a liquid biopsy sample and search for different types of markers that can help a physician manage disease,” explained CBM director Steven Soper. “To give you an example, this little chip is used to isolate tumour cells out of the blood of cancer patients. A physician will take a sample of blood from the patient, put it into the chip to enrich the tumour cells from the blood sample — there’s very few of them, maybe about 10 or so — and then we open those cells to look at the genetic composition to help decide: does the patient have a disease, how to treat the disease, is the patient responding to therapy?”
Reduce preclinical failures with smarter off-target profiling
24 September 2025 | 15:00PM BST | FREE Webinar
Join this webinar to hear from Dr Emilie Desfosses as she shares insights into how in vitro and in silico methods can support more informed, human-relevant safety decisions -especially as ethical and regulatory changes continue to reshape preclinical research.
What you’ll learn:
- Approaches for prioritizing follow-up studies and refining risk mitigation strategies
- How to interpret hit profiles from binding and functional assays
- Strategies for identifying organ systems at risk based on target activity modulation
- How to use visualization tools to assess safety margins and compare compound profiles
Register Now – It’s Free!


The Center of BioModular Multi-Scale Systems for Precision Medicine, dubbed CBM2, takes small plastic chips made of the same material as a compact disc and transforms them into marvels of engineering and chemistry that quickly can detect hard-to-diagnose human diseases using saliva, urine or blood from a patient
[Credit: University of Kansas].
The researchers how that the lab-on-a-chip technology has the potential to improve and save lives, as well as benefiting patients while strengthening the Kansas economy.
Related topics
Big Data, Bioinformatics, Biopharmaceuticals, Lab Automation, Lab-on-a-Chip
Related organisations
National Institute of Biomedical Imaging and Bioengineering (NIBIB), The Center of BioModular Multi-Scale Systems for Precision Medicine, University of Kansas, US National Biotechnology Resource (P41) Center, US National Institutes of Health (NIH)
Related people
Steven Soper